Recent Company News

• 05:55 PM ET Jan 15, 2026
  

  FDA grants orphan drug designation to ifinatamab deruxtecan in treatment of esophageal cancer (¥3401.0000, 0)

• 07:47 AM ET Jan 13, 2026
  

  Daiichi Sankyo doses first patient in TROPION-Lung17 phase 3 trial of DATROWAY (datopotamab deruxtecan) (¥3540.0000, 0)

• 05:01 PM ET Jan 12, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:33 AM ET Jan 08, 2026
  

  Organon to commercialize Daiichi Sankyo's Nilemdo in six European countries; terms undisclosed ($8.19, 0.00)

• 02:41 AM ET Jan 07, 2026
  

  Daiichi Sankyo, GENESIS Pharma enter exclusive license and supply agreement for VANFLYTA in 13 CEE markets (¥3470.0000, 0)

• 01:59 AM ET Jan 05, 2026
  

  StreetAccount Sector Summary - China Healthcare December Recap

• 12:42 PM ET Jan 02, 2026
  

  Daiichi Sankyo reportedly to spend ~¥300B on establishing additional production facilities in the US, Japan, China, and Germany -- Nikkei (¥3348.0000, 0)

• 09:52 AM ET Jan 02, 2026
  

  Germany's IQWiG says trastuzumab deruxtecan shows considerable added benefit for gastric cancer

• 02:50 AM ET Dec 25, 2025
  

  AstraZeneca and Daiichi Sankyo's Enhertu receives NMPA approval in China (13674.0000p, 0)

• 08:44 AM ET Dec 22, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market